CardioSource WorldNews | Page 54

Continued from page 44 Preston/Stokes have several times challenged the obesity paradox, most recently in suggesting that looking at weight change over time (as opposed to weight at a single point in time) lowers the predictive power of obesity and makes overweight and obesity appear less harmful than they really are.5 Can you respond to this challenge? Confounders are probably important considerations, but many studies show the obesity paradox after correcting for leading confounders. Also non-purposeful weight loss is probably a bad thing and is associated with high risk, and the Stokes/ Preston papers do not differentiate purposeful from nonpurposeful weight loss. The perfect case would be long-term lean and fit. However, this is not very helpful for the 75% of society and our patients who are sitting in front of us now being overweight or obese (currently, obesity is present in 36% of U.S. adults). Would Preston and Stokes suggest that the obese not lose weight? This is their highest risk group: those who were previously heavier and now have lower weight. For the patients we see on a daily basis, I think it is much more important and helpful to give the messages and advice I’ve already discussed. And although the data from Stokes and Preston may have some accuracy, it does not at all help us care better for our many patients who are currently carrying 20, 30, or even 40 extra pounds, whereas the advice from my research could be very useful. REFERENCES: 1. Lavie CJ, Osman AF, Milani RV, Mehra MR. Am J Cardiol. 2003;91:891-4. 2. Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Heart. 2015;101:1631-8. 3. Lavie CJ, De Schutter A, Milani RV. Heart. 2015;101:1610-1. 4. Tomiyama AJ, Hunger JM, Nguyen-Cuu J, et al. Int J Obes (Lond). 2016 Feb. 4. [Epub ahead of print] 5. Stokes A, Preston SH. Proc Natl Acad Sci USA. 2016;113:572-7. Related Research Telomeres Go Both Ways Telomere shortening is involved with all aspects of the aging process on a cellular level. Lifestyle factors including smoking, unhealthy diet, and lack of exercise appear to increase the pace of telomere shortening. Obesity also contributes to telomere attrition, although a causal relationship has not been established.1 On the flip side, the Mediterranean diet has been associated with longer telomere length.2 But a new study in the International Journal of Obesity showed that telomere length actually increased after weight loss induced by bariatric surgery.3 Investigators followed 142 bariatric surgery patients for more than 10 years, using normal weight individuals matched by age and sex as controls. “During 10 years of pronounced and sustained weight loss, relative telomere length increased by 0.024 ± 0.14 (p = 0.047) in bariatric patients (aged 29-79 years),” wrote Laimer et al. Telomere length decreased from baseline over the same period in the controls. bama at Birmingham investigators reported for the first time an association between verapamil use and lower fasting glucose levels in humans with diabetes.6 (They previously showed that verapamil completely reverses the disease in mice models.) They evaluated 5,000 adults with diabetes who were part of the National Institutes of Health-sponsored REGARDS study (Reasons for Geographic and Racial Differences in Stroke). Calcium-channel blocker (CCB) users had 5 mg/dl lower serum glucose compared to nonusers and verapamil users had on average 10 mg/dl lower serum glucose compared to CCB nonusers. The effect was strongest for verapamil users who took insulin alone to manage their diabetes; they showed a 37 mg/dl lower serum glucose. A Diabetes/AF Conundrum One to the Gut We mentioned atrial fibrillation as it relates to obesity and why diabetes is an important CV ‘multiplier’ of risk. In the January 26, 2016, issue of JACC, Ashburner et al. looked at diabetes and stroke risk.4 Diabetes is usually considered a dichotomous measure that uniformly appears as a risk marker in risk scores. The authors explored the duration of diabetes, the extent of diabetes control, and the likelihood of ischemic stroke among persons with diabetes and AF during periods when the observed population was not receiving warfarin. They found that individuals with AF who have had diabetes for 3 or more years had 1.74-fold more strokes than those with diabetes of shorter duration, while event rates were similar among diabetic persons with HbA1c < 7%, 7% to 8.9%, and > 9%. Their findings suggest that glycemic control is not relevant to macrovascular event rates, while non-glycemic factors are present among persons with diabetes and have progressively greater effect with increasing time. As you might imagine, this is controversial, so for a further perspective, read the accompanying commentary by Bloomgarden and Bansilal.5 The contribution of the gut microbiota (intestinal bacterial strains) in the developContinued on page 54 TABLE Pathogenic Gut Flora in HC and CHF Patients Candida Campylobacter Shigella Salmonella Yersinia enterocolitica % of patients having pathogens in stool HC 8 12 16 0 0 Total CHF 33.3 79.1 37.5 38.7 32.8 NYHA I to II 8.9 58.4 33.3 41.2 33.6 NYHA III to IV 92.0 96.3 40.5 36.2 32.0 Colony-forming units/ml (×105) of stool  HC 0.8 ± 0.4 1.0 ± 0.3 1.6 ± 0.2 0 0  Total CHF 21.3 ± 1.6∗ 85.3 ± 3.7∗ 38.9 ± 12.3∗ 31.3 ± 9.1∗ 22.9 ± 6.3∗  NYHA I to II  NYHA III to IV 2.9 ± 1.1 8.3 ± 1.3† 7.9 ± 1.7† 20.2 ± 4.9∗ 23.1 ± 5.9∗ 37.2 ± 4.4∗‡ 164.0 ± 6.1∗‡ 70.4 ± 17.2∗‡ 37.6 ± 13.1∗ 24.8 ± 7.5∗ Verapamil Lowers Glucose Levels *p < 0.001, total patients with chronic heart failure (CHF) vs healthy control: subjects (HC), NYHA III to IV versus HC. †p < 0.01, NYHA I to II versus HC. ‡p < 0.001, NYHA III to IV versus NYHA I to II. ‡p < 0.01, NYHA III to IV versus NYHA I to II. As this issue of CSWN was going to press, University of Ala- NYHA = New York Heart Association. 52 CardioSource WorldNews March 2016